{"contacts": [{"terms": [{"accession": "MS:1000586", "name": "contact name", "value": "Samantha Swenson"}, {"accession": "MS:1000589", "name": "contact email", "value": "samantha.swenson@unmc.edu"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "University of Nebraska Medical Center"}, {"accession": "MS:1002037", "name": "dataset submitter"}]}, {"terms": [{"accession": "MS:1002332", "name": "lab head"}, {"accession": "MS:1000586", "name": "contact name", "value": "Shannon Mychel Buckley"}, {"accession": "MS:1000589", "name": "contact email", "value": "shannon.buckley@unmc.edu"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Department of Genetics, Cell Biology, & Anatomy Buckley Lab University of Nebraska Medical Center Omaha, Nebraska United States of America"}]}], "datasetFiles": [{"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD014387/20190130_Buckley_F1_7.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD014387/20190130_Buckley_F2_8.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD014387/20190130_Buckley_F3.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD014387/20190130_Buckley_F4.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD014387/20190130_Buckley_F5.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD014387/20190130_Buckley_F6.raw"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD014387/Fbxo9 January TMT proteins only.xlsx"}], "description": "The hematopoietic system is maintained throughout life by hematopoietic stem cells that are capable of differentiation to all hematopoietic lineages. An intimate balance between self-renewal, differentiation, and quiescence is required to maintain hematopoiesis. Disruption of this balance can result in hematopoietic malignancy, including acute myeloid leukemia (AML). FBXO9, from the F-box ubiquitin E3 ligases, is down-regulated in patients with AML compared to normal bone marrow. FBXO9 is a substrate recognition component of the Skp1-Cullin-F-box (SCF)-type E3 ligase complex. FBXO9 is highly expressed in hematopoietic stem and progenitor populations, which contain the tumor-initiating population in AML. In AML patients, decrease in FBXO9 expression is most pronounced in patients with the inversion of chromosome 16 (Inv(16)), a rearrangement that generates the transcription factor fusion gene, CBFB-MYH11. To study FBXO9 in malignant hematopoiesis, we generated a conditional knockout mouse model using a novel CRISPR/Cas9 strategy. Our data shows that deletion of Fbxo9 in mice expressing Cbfb-MYH11 leads to markedly accelerated and aggressive leukemia development. In addition, we find loss of FBXO9 leads to increased proteasome expression and tumors are more sensitive to bortezomib suggesting that FBXO9 expression may predict patient response to bortezomib treatment.", "fullDatasetLinks": [{"accession": "MS:1002852", "name": "Dataset FTP location", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD014387"}, {"accession": "MS:1001930", "name": "PRIDE project URI", "value": "http://www.ebi.ac.uk/pride/archive/projects/PXD014387"}], "identifiers": [{"accession": "MS:1001919", "name": "ProteomeXchange accession number", "value": "PXD014387"}], "instruments": [{"accession": "MS:1002732", "name": "Orbitrap Fusion Lumos"}], "keywords": [{"accession": "MS:1001925", "name": "submitter keyword", "value": "FBXO9 AML Inv(16) Spleen"}], "modifications": [{"accession": "MOD:01720", "name": "TMT6plex-126 reporter+balance reagent acylated residue"}, {"accession": "MOD:00492", "name": "ubiquitination signature dipeptidyl lysine"}, {"accession": "MOD:00696", "name": "phosphorylated residue"}, {"accession": "MOD:00425", "name": "monohydroxylated residue"}, {"accession": "MOD:00397", "name": "iodoacetamide derivatized residue"}], "publications": [{"terms": [{"accession": "MS:1000879", "name": "PubMed identifier", "value": "31684170"}, {"accession": "MS:1002866", "name": "Reference", "value": "Hynes-Smith RW, Swenson SA, Vahle H, Wittorf KJ, Caplan M, Amador C, Hyde RK, Buckley SM. Loss of FBXO9 Enhances Proteasome Activity and Promotes Aggressiveness in Acute Myeloid Leukemia. Cancers (Basel). 2019 11(11)"}]}], "species": [{"terms": [{"accession": "MS:1001469", "name": "taxonomy: scientific name", "value": "Mus musculus (Mouse)"}, {"accession": "MS:1001467", "name": "taxonomy: NCBI TaxID", "value": "10090"}]}], "title": "FBXO9 in Murine Inversion 16 AML"}